PMID- 10868556
OWN - NLM
STAT- MEDLINE
DCOM- 20001012
LR  - 20190921
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 22
IP  - 5
DP  - 2000 May
TI  - Doses of olanzapine, risperidone, and haloperidol used in clinical practice: 
      results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio 
      Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
PG  - 583-99
AB  - OBJECTIVE: The objectives of this study were to determine the doses of olanzapine 
      (OLZ), risperidone (RIS), and haloperidol (HAL) used in clinical practice in 
      outpatients with schizophrenia and the rates of occurrence of extrapyramidal 
      symptoms (EPS) and other adverse events, clinical response, and use of 
      concomitant medications. METHODS: The present study involved a subset of patients 
      from a 6-month, open-label, prospective observational study. Data were collected 
      by 293 psychiatrists at mental health centers and other outpatient treatment 
      facilities in Spain. Medications and doses used, occurrence of EPS and other 
      adverse events, and scores on the Clinical Global Impression (CGI) of Severity 
      Scale and Global Assessment of Function (GAF) were recorded. Clinical response 
      was defined as a decrease of > or = 2 points on the CGI, with a final CGI score < 
      or = 4. RESULTS: A total of 2657 patients were included in the analysis. The 
      initial and overall mean daily doses for the 3 groups were as follows: OLZ, 12.2 
      and 13.0 mg, respectively; RIS, 5.2 and 5.4 mg; and HAL, 13.9 and 13.6 mg. 
      Initial and overall median daily doses were the same in each group: OLZ, 10 mg; 
      RIS, 6 mg; and HAL, 10 mg. A significantly lower proportion of OLZ-treated 
      patients (36.9%) experienced EPS compared with RIS-treated (49.6%) and 
      HAL-treated (76.0%) patients (P < or = 0.001). A significantly lower proportion 
      of patients in the OLZ group (47.8%) experienced adverse events compared with 
      patients in the RIS (57.2%) and HAL (79.8%) groups (P < or = 0.001). A 
      significantly greater proportion of OLZ-treated patients (37.3%) were responders 
      compared with RIS-treated patients (31.5%) (P < 0.05). In all 3 groups, patients 
      who had an initial CGI score > or = 5 received significantly higher overall mean 
      daily doses than did patients with an initial CGI score < 5 (P < 0.001). A 
      significantly lower proportion of OLZ-treated patients (10.2%) were receiving 
      concomitant anticholinergic medication at the end of the study (month 6) compared 
      with RIS-treated (19.9%) and HAL-treated (44.0%) patients (P < 0.001). 
      CONCLUSION: The mean daily doses recorded in this analysis based on data from a 
      naturalistic setting are consistent with recommendations based on clinical 
      trials. Compared with both RIS- and HAL-treated patients, OLZ-treated patients 
      were less likely to experience EPS or other adverse events, and less likely to 
      use concomitant anticholinergic medications. OLZ-treated patients were also more 
      likely to respond to treatment than were RIS-treated patients.
FAU - Sacristan, J A
AU  - Sacristan JA
AD  - Clinical Research Department, Lilly S.A., Madrid, Spain. sacristan_jose@lilly.com
FAU - Gomez, J C
AU  - Gomez JC
FAU - Montejo, A L
AU  - Montejo AL
FAU - Vieta, E
AU  - Vieta E
FAU - Gregor, K J
AU  - Gregor KJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Antipsychotic Agents)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 3G0285N20N (Pirenzepine)
RN  - J6292F8L3D (Haloperidol)
RN  - L6UH7ZF8HC (Risperidone)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
CIN - Clin Ther. 2000 Nov;22(11):1375-6. PMID: 11117662
MH  - Adult
MH  - Ambulatory Care
MH  - Antipsychotic Agents/*administration & dosage/adverse effects
MH  - Basal Ganglia Diseases/chemically induced
MH  - Benzodiazepines
MH  - Drug Utilization
MH  - Female
MH  - Haloperidol/administration & dosage/adverse effects
MH  - Humans
MH  - Male
MH  - Olanzapine
MH  - Pharmacoepidemiology
MH  - Pirenzepine/administration & dosage/adverse effects/*analogs & derivatives
MH  - Practice Patterns, Physicians'
MH  - Prospective Studies
MH  - Risperidone/administration & dosage/adverse effects
MH  - Schizophrenia/*drug therapy/epidemiology
EDAT- 2000/06/27 11:00
MHDA- 2000/10/14 11:01
CRDT- 2000/06/27 11:00
PHST- 2000/06/27 11:00 [pubmed]
PHST- 2000/10/14 11:01 [medline]
PHST- 2000/06/27 11:00 [entrez]
AID - S0149291800800466 [pii]
AID - 10.1016/s0149-2918(00)80046-6 [doi]
PST - ppublish
SO  - Clin Ther. 2000 May;22(5):583-99. doi: 10.1016/s0149-2918(00)80046-6.